TY - JOUR
T1 - Nutritional Support System (NSS) as a New Therapeutic Strategy for Cerebral Palsy
AU - Leal-Martinez, Fernando
AU - Ramirez, Guadalupe Jimenez
AU - Ibarra, Antonio
N1 - Publisher Copyright:
© 2024 Bentham Science Publishers.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Cerebral palsy (CP) is part of a group of nonprogressive motor disorders. The disease affects movement and posture and constitutes the most frequent cause of motor disability in childhood. CP is characterized by spasticity, reflecting lesions in the pyramidal pathway. Treatment is currently focused on physical rehabilitation, and the annual progression of the disease is 2-3%. About 60% of these patients present severe degrees of malnutrition associated with dysphagia, gastrointestinal ab-normalities, malabsorption, increased metabolism, and depression. These alterations promote sarcope-nia functional dependence and affect the quality of life and delay the evolution of motor skills. Cur-rently, there is evidence that the supplementation of several nutrients, dietary correction, and probiot-ics can improve neurological response by stimulating neuroplasticity, neuroregeneration, neurogene-sis, and myelination. This therapeutic strategy could shorten the response period to treatment and increase both gross and fine motor skills. The interaction of nutrients and functional foods integrating a Nutritional Support System (NSS) has shown greater efficiency in neurological stimulation than when nutrients are supplied separately. The most studied elements in the neurological response are gluta-mine, arginine, zinc, selenium, cholecalciferol, nicotinic acid, thiamine, pyridoxine, folate, cobalamin, Spirulina, omega-3 fatty acids, ascorbic acid, glycine, tryptophan, and probiotics. The NSS represents a therapeutic alternative that will restore neurological function in patients with spasticity and pyramidal pathway lesions, both characteristics of patients with CP.
AB - Cerebral palsy (CP) is part of a group of nonprogressive motor disorders. The disease affects movement and posture and constitutes the most frequent cause of motor disability in childhood. CP is characterized by spasticity, reflecting lesions in the pyramidal pathway. Treatment is currently focused on physical rehabilitation, and the annual progression of the disease is 2-3%. About 60% of these patients present severe degrees of malnutrition associated with dysphagia, gastrointestinal ab-normalities, malabsorption, increased metabolism, and depression. These alterations promote sarcope-nia functional dependence and affect the quality of life and delay the evolution of motor skills. Cur-rently, there is evidence that the supplementation of several nutrients, dietary correction, and probiot-ics can improve neurological response by stimulating neuroplasticity, neuroregeneration, neurogene-sis, and myelination. This therapeutic strategy could shorten the response period to treatment and increase both gross and fine motor skills. The interaction of nutrients and functional foods integrating a Nutritional Support System (NSS) has shown greater efficiency in neurological stimulation than when nutrients are supplied separately. The most studied elements in the neurological response are gluta-mine, arginine, zinc, selenium, cholecalciferol, nicotinic acid, thiamine, pyridoxine, folate, cobalamin, Spirulina, omega-3 fatty acids, ascorbic acid, glycine, tryptophan, and probiotics. The NSS represents a therapeutic alternative that will restore neurological function in patients with spasticity and pyramidal pathway lesions, both characteristics of patients with CP.
KW - cerebral palsy
KW - CP
KW - neurological function
KW - NSS
KW - Nutritional support system
KW - therapeutic strategy
UR - http://www.scopus.com/inward/record.url?scp=85182091316&partnerID=8YFLogxK
U2 - 10.2174/1871527322666230330124124
DO - 10.2174/1871527322666230330124124
M3 - Artículo
C2 - 37005522
AN - SCOPUS:85182091316
SN - 1871-5273
VL - 23
SP - 271
EP - 277
JO - CNS and Neurological Disorders - Drug Targets
JF - CNS and Neurological Disorders - Drug Targets
IS - 3
ER -